I, or the institutions with which I am associated, have in the past received funding from all actual and prospective insulin manufacturers, including Antriabio, AstraZeneca, Biocon (Viatris, Mylan), Eli Lilly, Gan & Lee, Merck (MSD)/Samsung, Novo Nordisk, and Sanofi for lecturing, advisory, or research activities, as well as from competing manufacturers of other glucose-lowering products (Boehringer Ingelheim, GlaxoSmithKline, Janssen, and Servier). I am grateful to colleagues for informative discussions in the area covered, but none in the process of writing this Comment. There has been no funding, and no commercial knowledge, of this activity.